Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma.

Cancers (Basel) · 2025 · PMC12427384 · PMID 40940903

Europe PMC DOI

hedged sentence

0.0505

closest p · 1.0× alpha

0.0505

boldest claim

The sentences

showed a trendp = 0.0505so close (0.05 < p ≤ 0.1)

For example, patients with musculoskeletal irAEs showed a trend towards an improved median PFS of 12 months (95% CI: 5-NA) compared to 5 months (95% CI: 4–8) ( p = 0.0505) in patients with any other irAE and a statistically significant higher PFS compared to patients without irAE (2 months, 95% CI: 1–8) ( p = 0.0068).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.